European Heart Journal Advance Access published online on February 8, 2007
European Heart Journal, doi:10.1093/eurheartj/ehl507
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP
1 Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Haartmaninkatu 4, POB 340, 00029 HUS, Helsinki, Finland
2 Division of Emergency Care, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
3 National Research and Development Centre for Welfare and Health (STAKES), Helsinki, Finland
4 Department of Medicine, Central Finland Central Hospital, Jyväskylä, Finland
5 Department of Cardiology, Kuopio University Hospital, Kuopio, Finland
6 Department of Clinical Chemistry, Helsinki University, Helsinki, Finland
Received 31 August 2006; revised 13 December 2006; accepted 12 January 2007.
* Corresponding author. Tel: +358 50 322 4094; fax: +358 9 47174015. E-mail address: johan.lassus{at}fimnet.fi
AIMS: Cystatin C, a novel marker of renal function, has been implicated as a prognostic marker in cardiovascular disease. We investigated the prognostic value of cystatin C in acute heart failure (AHF) in comparison to other markers of renal function and NT-proBNP.
METHODS AND RESULTS: Patients with cystatin C measurements (n = 480) from a prospective multicentre study on AHF were included. All-cause mortality at 12 months was 25.4%. Cystatin C, creatinine, age, gender, and systolic blood pressure on admission were identified as independent prognostic risk factors. Cystatin C above median (1.30 mg/L) was associated with the highest adjusted hazard ratio, 3.2 (95% CI 2.05.3), P < 0.0001. Mortality increased significantly with each tertile of cystatin C. Combining tertiles of NT-proBNP and cystatin C improved risk stratification further. Moreover, in patients with normal plasma creatinine, elevated cystatin C was associated with significantly higher mortality at 12 months: 40.4% vs. 12.6% in patients with both markers within normal range, P < 0.0001.
CONCLUSION: Cystatin C is a strong and independent predictor of outcome at 12 months in AHF. Furthermore, cystatin C identifies patients with poor prognosis despite normal plasma creatinine. Cystatin C seems to be a promising risk marker in patients hospitalized for AHF.
Key Words: Cystatin C Acute heart failure Prognosis Renal function Biomarkers
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. T Fung, A. M Wilson, F. Zhang, N. Harris, K. A Edwards, J. W Olin, and J. P Cooke A biomarker panel for peripheral arterial disease Vascular Medicine, August 1, 2008; 13(3): 217 - 224. [Abstract] [PDF] |
||||
![]() |
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2344 - 2351. [Full Text] [PDF] |
||||

